Catalyst Calendar

Fri, Jul 24, 2026

1 updates

6:15 AM

CHMP recommends EU approval of Roche’s Susvimo, the first continuous delivery treatment for neovascular age-related macular degeneration (nAMD)

Susvimo is the first and only continuous delivery treatment that offers an alternative to standard of care eye injections for nAMD Positive recommendation is based on data from the LADDER, Archway and Portal studies showing Susvimo maintained vision equivalent to monthly intravitreal ranibizumab injections 1-3 By continuously delivering medicine into the...

roche.com

Thu, Jul 23, 2026

1 updates

RHHBY

1:00 AM

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s strong momentum continues in the first half of 2026, delivering +6% sales growth at constant exchange rates; -2% in CHF due to the significant appreciation of the Swiss franc

Group sales were +6% at constant exchange rates (CER) 1 , -2% when reported in CHF and +8% in USD 2 , in the first six months, driven by high demand for innovative medicines and diagnostics. Pharmaceuticals Division sales were +6% at CER, -1% when reported in CHF and +8% in USD, due to continued high growth in sales of our medicines across disease areas;...

roche.com

Wed, Jul 15, 2026

1 updates

RHHBY

1:00 AM

FDA grants Priority Review to Roche’s Gazyva/Gazyvaro for adults with primary membranous nephropathy

Priority Review decision is based on phase III MAJESTY results, where Gazyva/Gazyvaro achieved significantly higher complete remission rates at two years compared to tacrolimus 1 If approved, Gazyva/Gazyvaro will be the first FDA-approved therapy for primary membranous nephropathy (pMN), following global approvals in lupus nephritis and ongoing regulatory...

roche.com

Tue, Jul 14, 2026

1 updates

RHHBY

1:00 AM

Roche introduces cobas Hepatitis D Virus (HDV) test, the first fully automated diagnostic solution to identify the most severe form of viral hepatitis

The new test enables clinicians to reliably diagnose HDV and monitor patients’ treatment response. Hepatitis D affects nearly 12 million of people globally and is considered the most aggressive form of viral hepatitis, often leading to liver failure and cancer faster than other types....

roche.com

Thu, Jul 9, 2026

1 updates

RHHBY

1:00 AM

Roche receives CE Mark for blood test to identify tuberculosis infection

The Elecsys IGRA TB test expands global access to tuberculosis infection testing, advancing progress toward the World Health Organization's elimination targets. Performed on Roche’s industry-leading and widely available cobas immunoassay systems, the test enables laboratories to meet growing tuberculosis infection testing needs by reducing reliance on...

roche.com

Tue, Jul 7, 2026

1 updates

RHHBY

1:00 AM

Roche presents new data in Alzheimer’s disease from across its integrated pharmaceutical and diagnostics portfolio at AAIC

Five oral presentations in a Featured Research Session will highlight trontinemab, including new long-term data from Phase Ib/IIa Brainshuttle TM AD study and design of Phase III PrevenTRON study in preclinical Alzheimer’s New data on Roche’s CE mark Elecsys pTau217 blood test will be presented on its use for Alzheimer's diagnosis in both primary and...

Presentation / Abstract • Phase 1/2AAIC oral presentation Tue, Jul 14, 2026, 2:00 PM BSTroche.com

Thu, Jul 2, 2026

1 updates

RHHBY

1:00 AM

[Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer

Phase III (Krascendo 1) demonstrates best-in-class potential for patients with previously treated advanced KRAS G12C non-small cell lung cancer Divarasib showed clinically meaningful improvements in progression-free survival compared to approved KRAS G12C inhibitors;...

Trial Results • Phase 3roche.com

Tue, Jun 30, 2026

1 updates

RHHBY

1:00 AM

FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)

The filing application is based on improvements seen across key efficacy endpoints from the global phase III SatraGO-1 and SatraGO-2 studies, including proptosis (bulging eyes) and diplopia (double vision) in active TED Enspryng (satralizumab) has the potential to become the first at-home subcutaneous disease-modifying standard of care for TED TED is an...

roche.com

Mon, Jun 29, 2026

1 updates

RHHBY

1:00 AM

Roche announces the launch of AXELIOS 1, a transformative next-generation sequencing platform

AXELIOS 1 delivers a unique combination of accuracy, speed, scalability and cost efficiency, giving laboratories of all sizes the freedom to customise their workflows and explore a wider array of applications....

roche.com

Thu, Jun 18, 2026

1 updates

RHHBY

1:00 AM

FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma

Filing acceptance based on data from the phase III SUNMO study where subcutaneous Lunsumio VELO plus Polivy demonstrated a 59% reduction in risk of disease progression or death 1 People with relapsed or refractory LBCL represent one of the highest unmet need populations in lymphoma and require timely access to effective therapies If approved, this...

roche.com

Fri, Jun 12, 2026

1 updates

RHHBY

3:15 PM

Roche receives FDA approval for the first companion diagnostic to assess PTEN protein in people living with prostate cancer

The new VENTANA PTEN (SP218) RxDx Assay fulfils an unmet medical need by helping clinicians identify patients with PTEN protein loss who may benefit from combination treatment with TRUQAP In prostate cancer, PTEN protein loss is associated with faster disease progression and reduced benefit from current standard-of-care treatments 1 The FDA approval...

roche.com

Thu, Jun 11, 2026

1 updates

RHHBY

1:00 AM

FDA grants Priority Review for Roche’s Tecentriq for a certain type of stage III colon cancer

Filing acceptance is based on the phase III Alliance ATOMIC study showing Tecentriq plus chemotherapy reduced recurrence or death risk by 50% versus chemotherapy alone 1 Nearly one in three patients with stage III colon cancer relapse within five years, highlighting a critical need for new adjuvant treatment options 2,3 If approved, Tecentriq plus...

roche.com

Mon, Jun 8, 2026

1 updates

RHHBY

1:00 AM

Roche announces global collaboration with Nurix Therapeutics to co-develop and co-commercialise potential best-in-class BTK degrader bexobrutideg across malignant haematology, immunology and neurology

Agreement offers potential best-in-class targeted protein degrader therapy option for people living with B-cell malignancies Collaboration adds to Roche’s oncology pipeline and offers potential indications in immunology (chronic spontaneous urticaria) and neurology (multiple sclerosis) Bexobrutideg utilises a novel approach to eliminate the Bruton’s...

roche.com

Tue, Jun 2, 2026

1 updates

RHHBY

1:00 AM

FDA accepts New Drug Application for Roche’s giredestrant in ER-positive early-stage breast cancer, the first and only oral SERD with positive phase III results in the curative setting

Filing acceptance, under priority review, based on phase III data showing giredestrant reduced the risk of invasive disease recurrence or death by 30% compared with standard-of-care endocrine therapy 1 Giredestrant represents the first significant advance in adjuvant endocrine therapy in over 20 years 1-3 Giredestrant has the potential to become a new...

roche.com

Mon, Jun 1, 2026

1 updates

RHHBY

1:00 AM

Roche to present new data advancing its obesity portfolio at the American Diabetes Association’s 2026 Scientific Sessions

Late-breaking Phase II data highlight enicepatide’s (CT-388) efficacy and safety, reinforcing its potential to deliver best-in-class weight loss across a broad population of people living with overweight or obesity Late-breaking data from the Phase II ZUPREME-1 trial showcase petrelintide’s efficacy, safety, and compelling tolerability profile, which has...

Presentation / Abstract • Phase 2Late Breaking Poster Session Sun, Jun 7, 2026, 12:30 PM CTroche.com

Wed, May 27, 2026

1 updates

RHHBY

1:00 AM

Roche launches the Liver Disease Panel, the first suite of certified algorithms to support Chronic Liver Disease management

Roche introduces the first comprehensive library of certified healthcare algorithms to support chronic liver disease (CLD) management The Liver Disease Panel includes LiverPRO—a certified algorithm developed by the health tech company Evido—requiring only age and routine blood markers for the timely detection of liver fibrosis With CLD affecting 1.5 billion...

roche.com

Tue, May 19, 2026

1 updates

RHHBY

1:00 AM

Roche to present new data at ASCO 2026, reinforcing giredestrant's potential to transform the treatment paradigm in early breast cancer

New giredestrant data from the lidERA study on its potential as a new standard of care for adjuvant ER-positive breast cancer across all menopausal stages Primary results from the persevERA study on the numerical improvement in progression-free survival observed with first-line giredestrant plus palbociclib in advanced, endocrine-sensitive disease Overall,...

Presentation / Abstract • Phase 3ASCO oral presentation Sat, May 30, 2026, 1:39 PM CDTroche.com